Chair in Emerging Technologies 2021
The Stevens Group is very active in the development of bioengineering strategies for the biosensing and regenerative medicine fields. Prof Stevens aims to develop next generation biosensing technology platforms including a new MTAS (Multidimensional Target Agnostic Sensing) platform. Working closely with clinical and industrial partners, research will enable applications in point-of-care diagnostics, disease profiling and monitoring of biotech processes.
Personal website: https://www.imperial.ac.uk/people/m.stevens